Results 31 to 40 of about 455 (167)

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*

British Journal of Dermatology, Volume 187, Issue 3, Page 338-352, September 2022., 2022
Baricitinib 4 mg + TCS improved the signs and symptoms of moderate‐to‐severe AD through 52 weeks of treatment in patients with inadequate response, intolerance or contraindication to CA. The safety profile was consistent with previous studies of baricitinib in moderate‐to‐severe AD.
Thomas Bieber, Kristian Reich, Carle Paul, Yuichiro Tsunemi, Matthias Augustin, Jean‐Philippe Lacour, Pierre‐Dominique Ghislain, Yves Dutronc, Ran Liao, Fan E. Yang, Dennis Brinker, Amy M. DeLozier, Eric Meskimen, Jonathan M. Janes, Kilian Eyerich, on behalf of theBREEZE‐AD4 study group   +15 more
wiley   +1 more source

An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 36, Issue 9, Page 1486-1496, September 2022., 2022
Abstract Background Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus. Objectives This study examined treatment‐emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 ...
T. Werfel, A.D. Irvine, C. Bangert, J. Seneschal, S. Grond, T. Cardillo, D. Brinker, J. Zhong, E. Riedl, A. Wollenberg   +9 more
wiley   +1 more source

Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function

Journal of Cutaneous Immunology and Allergy, Volume 5, Issue 2, Page 38-46, April 2022., 2022
The study by Abe et al examines the effects of delgocitinib 0.5% ointment treatment on skin rash severity and skin‐barrier function in adult patients with mild‐moderate AD. Partial eczema area and severity index (pEASI) score, stratum corneum hydration (SCH) and trans‐epidermal water‐loss (TEWL) were examined.
Masatoshi Abe, Hajime Iizuka, Ikue Nemoto‐Hasebe, Osamu Nemoto, Hiroyuki Toyama, Katsuyo Ohashi‐Doi, Kenji Kabashima   +6 more
wiley   +1 more source

Eczema herpeticum emerging during atopic dermatitis in infancy [PDF]

, 2020
Background. Eczema herpeticum (EH) is an acute disseminated viral infection that develops in the presence of an existing skin lesion, often on the ground of atopic dermatitis (AD).
Aysegül Ertuğrul, Ezgi Ulusoy Severcan, İlknur Bostancı, Serap Özmen, Zeynep Şengül Emeksiz   +4 more
core   +2 more sources

Tzanck smears: an old but useful diagnostic tool [PDF]

, 2009
A citologia de Tzanck consiste em método simples e confiável para o diagnóstico de dermatoses virais, parasitárias, autoimunes e tumorais. Para exemplificar o emprego do teste de Tzanck em lesões vésico-bolhosas, um caso de pênfigo vulgar é descrito ...
ARRUDA, Darlene, BRITO, Moema Mignac Cumming, COSTA, Roberto Silva, ROSELINO, Ana Maria, TARQUÍNIO, Daniela Chaves   +4 more
core   +3 more sources

A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis

The Journal of Dermatology, Volume 48, Issue 11, Page 1640-1651, November 2021., 2021
Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions. In Japan, treatment options, such as topical corticosteroids and tacrolimus, are associated with efficacy and safety concerns. Crisaborole ointment, 2%, is a topical non‐steroidal anti‐inflammatory agent approved in several
Kayo Fujita, Michio Yagi, Shinichi Moriwaki, Mizuki Yoshida, Daniela Graham   +4 more
wiley   +1 more source

Eczema herpeticum in atopic dermatitis

Allergy, Volume 76, Issue 10, Page 3017-3027, October 2021., 2021
Abstract Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases leading to pruritic skin lesions. A subset of AD patients exhibits a disseminated severe HSV infection called eczema herpeticum (EH) that can cause life‐threatening complications. This review gives an overview of the clinical picture, and characteristics of the
Stephan Traidl, Lennart Roesner, Jana Zeitvogel, Thomas Werfel   +3 more
wiley   +1 more source

Psoriasis herpeticum due to Varicella zoster virus: A Kaposi′s varicelliform eruption in erythrodermic psoriasis

Indian Journal of Dermatology, 2012
Kaposi′s varicelliform eruption (KVE) or eczema herpeticum is characterized by disseminated papulovesicular eruption caused by a number of viruses like Herpes simplex virus I and II, Coxsackie virus, and Vaccinia and Small pox viruses in patients with ...
Geeta Garg, Gurvinder P Thami
doaj   +1 more source

Localized psoriasis herpeticum: Case report and review of literature

Indian Dermatology Online Journal, 2011
Kaposi′s varicelliform eruption (KVE) is a widespread cutaneous eruption caused by viruses, especially herpes simplex virus in patients with pre-existing dermatoses. ′′Psoriasis herpeticum′′ refers to the rare occurrence of KVE in patients with psoriasis.
Mamatha George, Jaheersha Pakran, Uma Rajan, Sandhya George, Sumi Thomas   +4 more
doaj   +1 more source

Refractory pemphigus foliaceus associated with herpesvirus infection: case report [PDF]

, 2017
Pemphigus foliaceus (PF) is an autoimmune disease characterized by blistering of the skin. Infections caused by members of the herpesviridae family have been suggested as a possible triggering factor for pemphigus vulgaris (PV), but not for PF.
Fernandes, Nurimar C., Guimarães, Maria Angélica A. M., Rampinelli, Heloisa, Souza, Leandro Magalhães de   +3 more
core   +3 more sources